May 27, 2025 12:48 PM EDTUpdated 01:06 PM
People
Law

Ser­no­va chair re­signs fol­low­ing in­sid­er trad­ing in­dict­ment over No­var­tis-Chi­nook deal

Zachary Brennan

Senior Editor

Cana­di­an cell ther­a­py biotech Ser­no­va said Sun­day that its board chair­man Ross Haghigh­at has re­signed af­ter be­ing in­dict­ed by the De­part­ment of Jus­tice

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

A new dawn for psy­che­delics? Com­pass could be the first to find out

Weeks af­ter TIG­IT fail, iTeos de­cides to wind down

The fate of Mod­er­na’s next-gen Covid shot looms large af­ter a flur­ry of pol­i­cy changes

Up­dat­ed: MD An­der­son-al­lied in­vest­ment firm tar­gets $250M for sec­ond can­cer biotech fund

GSK, Spero re­port Phase 3 win for UTI an­tibi­ot­ic; Sper­o's stock soars

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times